Search Results

You are looking at 131 - 140 of 205 items for :

  • "lymph node dissection" x
  • Refine by Access: All x
Clear All
Full access

Douglas B. Johnson and Jeffrey A. Sosman

patient underwent a completion axillary lymph node dissection with 2 additional lymph nodes with melanoma involvement; extracapsular extension was not identified (TxN2b; AJCC stage IIIB). Detailed physical examination did not reveal a primary site of

Full access

Vijaya Raj Bhatt, Mojtaba Akhtari, R. Gregory Bociek, Jennifer N. Sanmann, Ji Yuan, Bhavana J. Dave, Warren G. Sanger, Anne Kessinger, and James O. Armitage

right breast cancer diagnosed 3 years before presentation, which was treated with mastectomy, sentinel lymph node dissection, and adjuvant cyclophosphamide and doxorubicin (4 cycles); the patient subsequently underwent maintenance therapy with oral

Full access

Michelle T. Ashworth and Adil Daud

chest, abdomen, and pelvis identified no other lesions, and results of a complete right inguinal lymph node dissection were negative. The patient was treated with adjuvant radiotherapy (XRT), complicated by a nonhealing ulcer for 1 year and persistent

Full access

Aysegul A. Sahin, Timothy D. Gilligan, and Jimmy J. Caudell

with retroperitoneal lymph node dissection only? Which patients with stage II and III disease will need to undergo resection of residual masses after chemotherapy?” he continued. Dr. Gilligan explained that the 8th edition has made some changes, but

Full access

Eleni Efstathiou and Christopher J. Logothetis

-chemotherapy retroperitoneal lymph node dissection . Br J Cancer 1999 ; 80 : 249 – 255 . 55. Howell SJ Shalet SM . Spermatogenesis after cancer treatment: damage and recovery . J Natl Cancer Inst Monogr 2005 ; 34 : 12 – 17 . 56. Brydoy M Fossa SD

Full access

James Mohler, Robert R. Bahnson, Barry Boston, J. Erik Busby, Anthony D'Amico, James A. Eastham, Charles A. Enke, Daniel George, Eric Mark Horwitz, Robert P. Huben, Philip Kantoff, Mark Kawachi, Michael Kuettel, Paul H. Lange, Gary MacVicar, Elizabeth R. Plimack, Julio M. Pow-Sang, Mack Roach III, Eric Rohren, Bruce J. Roth, Dennis C. Shrieve, Matthew R. Smith, Sandy Srinivas, Przemyslaw Twardowski, and Patrick C. Walsh

decision-making for men contemplating active surveillance, 12 radical prostatectomy, 13 – 15 neurovascular bundle preservation, 16 – 18 or omission of pelvic lymph node dissection (PLND) during radical prostatectomy, 19 brachytherapy, 13 , 20 , 21 or

Full access

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt-Marie Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Jasgit Sachdev, Mary Lou Smith, George Somlo, John H. Ward, Antonio C. Wolff, and Richard Zellars

pregnant during breast cancer treatment (see page 160). Locoregional Treatment Several randomized trials document that mastectomy with axillary lymph node dissection is equivalent to breast-conserving therapy with lumpectomy, axillary dissection

Full access

David D. Buethe and Julio Pow-Sang

RP and pelvic lymph node dissection. Other reports confirm this observation. 17 , 23 , 28 Inspection of whole-mount prostatectomy specimens has previously shown a significant indirect correlation between percent-free PSA and prostate cancer volume

Full access

Derek J. Erstad, Mariela Blum, Jeannelyn S. Estrella, Prajnan Das, Bruce D. Minsky, Jaffer A. Ajani, Paul F. Mansfield, Naruhiko Ikoma, and Brian D. Badgwell

; 11 : 439 – 449 . 20409751 10.1016/S1470-2045(10)70070-X 6. Seevaratnam R , Bocicariu A , Cardoso R , A meta-analysis of D1 versus D2 lymph node dissection . Gastric Cancer 2012 ; 15 ( Suppl 1 ): S60 – 69 . 10.1007/s10120

Full access

Daphne Y. Lichtensztajn, John T. Leppert, James D. Brooks, Sumit A. Shah, Weiva Sieh, Benjamin I. Chung, Scarlett L. Gomez, and Iona Cheng

therapy (ADT), RT with brachytherapy with or without 2 to 3 years of ADT, or radical prostatectomy with pelvic lymph node dissection as initial treatment of all high-risk localized PCa, barring contraindications. 2 Despite these recommendations